229 related articles for article (PubMed ID: 32790723)
1. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH; Bodenbender J; Handle F; Diehl T; Donix L; Tsaur I; Gleave M; Haferkamp A; Huber J; Fuessel S; Juengel E; Culig Z; Thomas C
PLoS One; 2020; 15(8):e0237248. PubMed ID: 32790723
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
6. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
Peak TC; Panigrahi GK; Praharaj PP; Su Y; Shi L; Chyr J; Rivera-Chávez J; Flores-Bocanegra L; Singh R; Vander Griend DJ; Oberlies NH; Kerr BA; Hemal A; Bitting RL; Deep G
Mol Carcinog; 2020 Jan; 59(1):62-72. PubMed ID: 31674708
[TBL] [Abstract][Full Text] [Related]
7. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.
Udhane V; Maranto C; Hoang DT; Gu L; Erickson A; Devi S; Talati PG; Banerjee A; Iczkowski KA; Jacobsohn K; See WA; Mirtti T; Kilari D; Nevalainen MT
Mol Cancer Ther; 2020 Jan; 19(1):231-246. PubMed ID: 31548294
[TBL] [Abstract][Full Text] [Related]
9. Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.
Metz EP; Wilder PJ; Dong J; Datta K; Rizzino A
J Cell Physiol; 2020 Apr; 235(4):3731-3740. PubMed ID: 31587305
[TBL] [Abstract][Full Text] [Related]
10. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
Ware KE; Somarelli JA; Schaeffer D; Li J; Zhang T; Park S; Patierno SR; Freedman J; Foo WC; Garcia-Blanco MA; Armstrong AJ
Oncotarget; 2016 Aug; 7(31):50507-50521. PubMed ID: 27409172
[TBL] [Abstract][Full Text] [Related]
11. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
12. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
Lee HC; Ou CH; Huang YC; Hou PC; Creighton CJ; Lin YS; Hu CY; Lin SC
Oncogene; 2021 Apr; 40(13):2407-2421. PubMed ID: 33664454
[TBL] [Abstract][Full Text] [Related]
13. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
15. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
16. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
18. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.
Han Y; Huang W; Liu J; Liu D; Cui Y; Huang R; Yan J; Lei M
Theranostics; 2017; 7(7):1914-1927. PubMed ID: 28638477
[TBL] [Abstract][Full Text] [Related]
19. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
20. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
